HDAC inhibition has been demonstrated to abrogate resistance to a number of drugs including imatinib in CML cells and gefitinib and cisplatin in lung cancer cells (10). Here, HDAC9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.